Allergan BIOCELL Breast Implant Recall & BIA-ALCL Lawsuit: What You Need to Know in 2026

If you’ve had breast augmentation or reconstruction with a textured implant, the 2019 Allergan BIOCELL recall may affect you directly. This is not a niche legal story — it is a public health event that the FDA called unprecedented, involving a specific product link to a diagnosable cancer, a worldwide withdrawal from market, and an active federal multi-district litigation with nearly 1,500 pending cases as of 2025.

This analysis covers only verified facts: FDA records, federal court filings, and published medical data. It is not legal or medical advice; individual situations require a physician for medical decisions and a product liability attorney for legal ones.

---

What Actually Happened: The July 2019 Recall, Explained

The FDA’s unprecedented request

On July 24, 2019, the FDA formally requested that Allergan voluntarily recall all BIOCELL textured breast implants and tissue expanders from the U.S. market. The agency described this as the first time it had ever requested removal of a breast implant product — a statement that underscores how seriously regulators viewed the available evidence.

Allergan complied and extended the recall worldwide, meaning no country where BIOCELL products were sold was exempt. This was a Class II recall — a designation for situations where use of the product may cause temporary adverse health consequences, though the FDA data on BIA-ALCL deaths shows the consequences in some cases were far from temporary.

The recall did not require women who already had these implants to immediately remove them. The FDA’s position, consistent with ASPS guidance, was that the BIA-ALCL risk, while real, is low enough that asymptomatic patients should monitor rather than undergo unnecessary surgery.

What triggered the request?

The FDA’s stated basis was data showing that BIOCELL textured surfaces carried approximately 6 times the BIA-ALCL risk of other textured implants on the market. This was not new data in 2019 — researchers and plastic surgeons had been tracking the BIA-ALCL signal for years. The FDA’s decision to act came after accumulating case reports made the risk-benefit calculus clearly unfavorable for the BIOCELL surface design.

The lawsuit’s core factual allegation builds on this timeline: plaintiffs argue Allergan knew or should have known about this elevated risk well before 2019 and failed to provide adequate warnings.

Which products were recalled?

The recall covers Allergan Natrelle BIOCELL textured breast implants and tissue expanders, including:

• Saline-filled implants: Styles 163, 168, 363, 468
• Silicone gel-filled textured implants: 410 series, INSPIRA textured models, round textured gel-filled models
• Tissue expanders: Natrelle 133 series, McGhan Croissant expanders

Smooth-surface Allergan implants were not part of the recall. If your records show a smooth Allergan implant, you are not in the recalled product category — though you should still know your implant type and monitor for any breast changes.

---

BIA-ALCL: The Medical Reality

What this lymphoma actually is

BIA-ALCL is not breast cancer. That distinction matters clinically and legally. It is a T-cell non-Hodgkin’s lymphoma that develops in the fluid (seroma) or fibrous scar capsule surrounding a breast implant — not in breast glandular tissue.

When diagnosed early and confined to the capsule (Stage IA or IIA), the standard treatment is surgical removal of the implant plus the entire surrounding capsule as a single unit — called en bloc capsulectomy. At early stages, this surgery is often curative with no need for chemotherapy.

When BIA-ALCL has spread beyond the capsule (advanced stage), treatment escalates to include chemotherapy (commonly CHOP-based regimens), radiation therapy, or autologous stem cell transplant. Post-treatment, ASPS and the National Comprehensive Cancer Network (NCCN) recommend PET/CT follow-up imaging at 3-to-6-month intervals for at least two years.

The FDA numbers you should know

Based on FDA MAUDE reporting data:

Metric	Verified Figure
Global BIA-ALCL cases reported (as of August 2024)	~1,577
Deaths associated with BIA-ALCL globally	63–64
Share of cases linked to Allergan BIOCELL specifically	~85%
Median time from implant to BIA-ALCL diagnosis	8–10 years
Range of time from implant to diagnosis	1–22 years

These are self-reported numbers fed into the FDA’s adverse event system — the actual total may be higher due to underreporting.

Why textured surfaces raise the risk

The BIOCELL surface design used a salt-loss texturing process that created a particularly rough surface at the microscopic level. The prevailing hypothesis is that microparticle shedding from this surface triggers a chronic immune response that, over years, can drive malignant T-cell proliferation. Smooth-surface implants have not been confirmed as a standalone cause of BIA-ALCL in the peer-reviewed literature.

This is not proven causation in the legal sense — that debate is central to the MDL litigation — but it is the scientific model that supports both the FDA’s recall decision and the plaintiffs’ negligence claims.

---

How to Find Out Whether Your Implants Are Recalled BIOCELL

This is the single most important practical step for anyone who has had breast augmentation with a textured implant.

Step 1: Find your Device Identification Card

Most hospitals and surgery centers give patients a credit card-sized Device Identification Card at discharge. This card contains:

• Manufacturer name (Allergan, Inamed, or McGhan — all the same company at different points in history)
• Product style and model number (e.g., “Natrelle Style 410”)
• Lot number and serial number
• Date of surgery

If the manufacturer is one of those three names and the product description includes “BIOCELL” or “textured,” you likely have a recalled device in your body.

Step 2: Request your operative report

If you don’t have the card — you misplaced it, were never given one, or had surgery years before these tracking practices were standard — contact the hospital or ambulatory surgical center where the procedure was performed. Ask specifically for:

1. Your operative report — the surgeon’s written documentation of the procedure, which should identify the exact implant make, model, and lot number used
2. The Medical Device Tracking Form — U.S. facilities are legally required to maintain tracking records for implantable medical devices

What if my surgeon retired or the clinic closed?

The medical records obligation doesn’t disappear when a practice closes. In most states, physicians are required to transfer patient records to a custodian, another practitioner, or a medical records storage service, and to notify patients. Contact the hospital or surgical facility’s records department. If you’re working with an attorney, many medical device law firms have staff investigators who specialize in tracking down historical implant records.

Quick self-check table

Question	Yes	No
Was manufacturer Allergan, Inamed, or McGhan?	→ Proceed to next check	→ Likely not a BIOCELL recall issue
Does documentation say “BIOCELL” or “textured”?	→ Recalled product	→ Smooth implant, not recalled
Do you still have the implants?	→ Monitor regularly	→ May still have a claim if harmed
Any new persistent swelling, pain, or asymmetry?	→ See a physician now	→ Continue regular monitoring

---

Recognizing BIA-ALCL Symptoms

What to watch for — and when

BIA-ALCL almost always appears at least one year after implant placement, with most cases diagnosed at 8–10 years post-surgery. The disease is rare, but because the consequence of missing it can be severe, early recognition matters.

Key symptoms documented by ASPS and the Cleveland Clinic:

Primary warning sign:

• Sudden, persistent swelling of one breast — not both — that develops out of nowhere. This represents fluid accumulating between the implant and the capsule (a late-developing seroma). It’s the most common and distinctive early presentation.

Secondary signs:

• Persistent pain or tenderness in the affected breast
• New asymmetry between the two breasts that wasn’t there before
• A palpable lump in the breast or armpit (swollen lymph node)
• Skin changes — rash, redness, or thickening over the breast
• Capsular contracture — the breast feeling abnormally firm or distorted

Do not dismiss these symptoms as routine implant aging. If any appeared more than a year after your surgery, see a plastic surgeon or breast specialist.

The diagnostic pathway

A physician who suspects BIA-ALCL will typically:

1. Order ultrasound or MRI to identify fluid collections or masses
2. If fluid is found, perform fine needle aspiration — drawing out a sample for cytological analysis
3. Send the sample for CD30 immunohistochemistry (IHC) and flow cytometry testing — CD30 positivity and ALK negativity in T-cells confirms BIA-ALCL
4. If BIA-ALCL is confirmed, order PET/CT scanning to determine staging

---

The Federal Lawsuit: MDL 2921 Explained

What is a multi-district litigation?

An MDL is a federal procedural mechanism that consolidates thousands of similar lawsuits from across the country before a single judge for coordinated pre-trial proceedings — discovery, expert witness rulings, and bellwether trials. Each plaintiff retains their individual case; the MDL is not a class action where everyone shares an identical settlement.

The purpose is efficiency: rather than 1,400 different federal courts handling identical discovery disputes about Allergan’s internal safety documents, one judge handles them all.

The key facts about MDL 2921

Detail	Verified Information
Case name	In re: Allergan Biocell Textured Breast Implant Products Liability Litigation
MDL number	MDL No. 2921
Case number	2:19-md-02921
Court	U.S. District Court, District of New Jersey
Presiding judge	Judge Brian R. Martinotti
Active cases (July 2025)	~1,456
First bellwether trial date	October 19, 2026

The March 2021 ruling that kept the MDL alive

Allergan’s first major defense strategy was to argue federal preemption — the theory that because the FDA had approved these devices under its Premarket Approval (PMA) process, state-law tort claims were barred. If this argument had succeeded, the entire MDL would have collapsed.

In March 2021, Judge Martinotti issued a 121-page order largely rejecting Allergan’s preemption defense, finding that plaintiffs had adequately pleaded parallel claims — that Allergan violated the FDA’s own requirements. This ruling was a pivotal moment: it allowed most claims to proceed toward discovery and, eventually, trial.

What plaintiffs allege

The MDL lawsuits allege:

• Manufacturing defect: the BIOCELL surface design was inherently defective in that it shed microparticles capable of causing a lymphomatous immune response
• Failure to warn: Allergan knew or should have known about the elevated BIA-ALCL risk long before 2019 and failed to warn patients and physicians adequately
• Failure to report: plaintiffs allege Allergan delayed reporting adverse events to the FDA as required under federal device regulations

What’s happening in 2025–2026

The MDL is in the discovery and bellwether selection phase. Key recent developments:

• January 2025: New Case Management Order established monthly conferences to keep the docket moving
• Summer 2025: Mediation sessions were ordered before a judicial mediator to explore early resolution
• October 2026: First bellwether trial scheduled — one plaintiff, one case, jury decides. The outcome will not bind others but will provide a data point for settlement valuation across the entire docket

No global settlement has been announced as of this writing. Individual settlements have been reached in some cases (including at least one UK case resulting in a five-figure settlement in 2023), but no aggregate settlement fund comparable to what was seen in 3M Combat Arms or Philips CPAP has been established.

---

Who Qualifies to File a Lawsuit

Core eligibility requirements

A qualifying plaintiff generally must demonstrate:

1. Confirmed Allergan BIOCELL textured implants — verifiable via operative report, Device ID Card, or medical device tracking records
2. BIA-ALCL diagnosis — confirmed by pathology report showing CD30-positive lymphoma cells in pericapsular fluid or tissue, or significant complications requiring explant surgery
3. Damages — documented medical expenses, lost income, pain and suffering, emotional distress
4. Causal link — connecting the implants to the BIA-ALCL diagnosis or injury

Medical monitoring claims: a different category

Some women with confirmed BIOCELL implants but no BIA-ALCL diagnosis have pursued medical monitoring claims — asking courts to require Allergan to fund ongoing surveillance (regular ultrasounds, physician visits) given the elevated risk. These claims are recognized in some states and rejected in others; eligibility depends heavily on where you live and where the surgery was performed.

Statute of limitations: the real urgency

Claim type	Typical clock start	Typical window
BIA-ALCL personal injury	Date of diagnosis or implant removal	2–3 years (most states)
Discovery rule application	Date you knew or should have known of the link	Varies by state
Product liability	Varies — some states use injury date, some use sale date	1–6 years

The recall date (2019) is generally not the trigger for your statute of limitations on personal injury claims. If you were diagnosed with BIA-ALCL in 2024, your clock likely started in 2024. But this is state-specific — do not assume. One phone call to a product liability attorney costs nothing if the firm offers free consultations, and it can save your claim.

---

The Financial Picture: Costs, Coverage, and Contingency Fees

What explant surgery costs out of pocket

These figures are U.S. estimates only; costs vary significantly by region, surgeon, and case complexity:

Procedure	Estimated Cost Range
Basic implant removal only	$5,000 – $9,500
En bloc capsulectomy (implant + full capsule removal)	$8,000 – $15,000+
Explant + breast reconstruction	$15,000 – $30,000+
Chemotherapy + radiation (advanced BIA-ALCL)	$30,000 – $100,000+

What Allergan’s warranty covers (and doesn’t)

Allergan’s Natrelle ConfidencePlus warranty program provides:

• Up to $1,000 in reimbursement for BIA-ALCL diagnostic costs
• Up to $7,500 in surgical fee reimbursement for BIA-ALCL treatment
• Free replacement implants of a similar smooth-surface type for women who want the recalled textured implants exchanged

The gap between these figures and actual costs — particularly for en bloc surgery, reconstruction, and oncological treatment — is where civil litigation becomes financially material for many plaintiffs.

Insurance coverage

Health insurance may cover implant removal and BIA-ALCL treatment when deemed medically necessary. Coverage decisions vary by insurer and plan. The BIA-ALCL Patient Assistance Fund, established by the American Society of Aesthetic Plastic Surgery and ASPS, also provides financial support for uninsured or underinsured patients seeking surgical treatment.

How contingency fee arrangements work

Most product liability attorneys handling this type of case operate on a contingency fee basis:

• No upfront fees — the firm advances litigation costs
• Attorney fee: 33–40% of the gross recovery (settlement or verdict)
• If you lose: no attorney fees (verify expense reimbursement terms in the retainer agreement)

Practical example: if your case settles for $150,000 and the contingency rate is 35%, the attorney receives $52,500 and you receive $97,500 before deduction of advanced case expenses (filing fees, expert witness costs, etc.).

For mass tort cases in MDL, fee arrangements sometimes go through a common benefit fund structure that slightly adjusts the percentages — your attorney will explain this at the time of engagement.

---

Building a Strong Case: Documents to Gather Now

The difference between a strong case and a weak one often comes down to documentation. Start collecting immediately:

Medical evidence

• Operative report from your augmentation surgery
• Device Identification Card or implant label from your surgical file
• Any correspondence from your surgeon or Allergan about the recall
• Pathology report confirming BIA-ALCL (if diagnosed)
• Ultrasound, MRI, and/or PET/CT scan images and reports
• Treatment records: surgical notes, oncology consult notes, chemotherapy records

Financial evidence

• All medical bills related to diagnosis and treatment
• Explanation of Benefits (EOB) statements from your insurer
• Documentation of time missed from work
• Pay stubs or tax returns showing income before and after the illness

Personal documentation

• Pre-surgery and post-diagnosis photographs
• A journal or symptom log noting when you first noticed changes and how they progressed
• Records of any communication with Allergan regarding the recall or warranty claims

---

Mistakes That Can Damage Your Case

Posting about your case on social media. Anything you say publicly about your symptoms, emotional state, physical activities, or case strategy can be used by opposing counsel to minimize your damages claim. Adopt a strict no-posting policy until your case is resolved.

Removing implants before seeing a specialist. If you have no symptoms and rush to have implants removed based on fear alone, the surgery may be classified as prophylactic — which weakens the causal link between the implants and documented harm. Get a specialist’s documented recommendation first.

Waiting too long because you feel okay. The statute of limitations does not pause because your BIA-ALCL is asymptomatic or slowly progressing. If you have a diagnosis, consult an attorney within weeks, not months.

Relying solely on Allergan’s warranty program. The Natrelle ConfidencePlus program is separate from civil litigation. Accepting warranty reimbursement does not automatically waive your lawsuit rights, but review any warranty claim documentation with an attorney first — some releases of claims language may appear in unexpected places.

Hiring a generalist attorney. Product liability MDL work requires experience with bellwether strategy, Daubert expert witness challenges, and coordinated discovery. Ask any attorney you consult specifically about their experience in MDL 2921 or comparable medical device MDLs.

---

The Science of BIA-ALCL: What Researchers Have Established

How the disease mechanism is understood

The leading scientific model for BIA-ALCL pathogenesis involves a multi-step process driven by chronic antigen stimulation at the implant surface. BIOCELL’s specific salt-loss manufacturing process produced a surface texture with higher surface area and a distinctive pore structure compared to other texturing methods. This surface, in contact with the body’s immune system for years, is thought to shed microparticles that trigger persistent activation of T-lymphocytes — eventually, in a small subset of patients, this immune overstimulation crosses into malignant transformation.

The CD30 biomarker is central to diagnosis. CD30 is a cell surface protein normally expressed on activated immune cells but present at unusually high levels in BIA-ALCL cells. Its absence essentially rules out the diagnosis; its presence in combination with ALK negativity confirms it. This single immunohistochemical test is why needle aspiration of late seromas is so diagnostically efficient when done correctly.

What the 85% BIOCELL attribution tells us

The finding that approximately 85% of all global BIA-ALCL cases are linked to Allergan BIOCELL is not coincidental. Other manufacturers also produced textured implants, yet none produced a device with the same signal. This concentration of risk around a single manufacturer’s surface design is the empirical basis for the MDL litigation’s negligence theories — and it is what survived Allergan’s initial attempts to dismiss the cases on federal preemption grounds.

ALK negativity and why it matters prognostically

BIA-ALCL is consistently ALK-negative — meaning it does not carry the chromosomal rearrangement involving the anaplastic lymphoma kinase gene that characterizes certain other forms of ALCL. ALK-negative ALCL is generally considered more aggressive when it arises in the traditional lymph node setting. In BIA-ALCL, however, because the disease begins in a localized capsular environment, early-stage ALK-negative BIA-ALCL still responds extremely well to complete surgical removal alone, with survival rates exceeding 95% at early stages. It is only when the disease escapes the capsule — into lymph nodes, distant organs, or soft tissue — that prognosis deteriorates markedly.

---

Staging of BIA-ALCL: What Stage Means for Treatment and Litigation

The National Comprehensive Cancer Network (NCCN) and ASPS use a staging system adapted from lymphoma classification:

Stage	Description	Standard Treatment	Typical Outcome
IA	Tumor confined to the inner surface of the capsule (effusion only)	En bloc capsulectomy	Excellent; often curative
IB	Tumor extends to outer surface of capsule	En bloc capsulectomy ± margin clearance	Very good
IIA	Lymph node involvement	Capsulectomy + lymph node dissection	Good with aggressive surgery
IIB	Capsule infiltration	Capsulectomy + adjuvant therapy	Moderate; may need chemo
III	Regional lymph nodes + spread beyond capsule	Multimodal (chemo, radiation)	Variable
IV	Distant organ involvement	Chemotherapy ± stem cell transplant	Guarded

Why staging matters to your lawsuit: Stage at diagnosis directly affects your documented damages. A Stage IA patient who undergoes en bloc removal and recovers fully has different provable damages than a Stage IV patient who undergoes months of chemotherapy, radiation, and potentially a stem cell transplant. Your medical records should capture the full extent of disease at diagnosis — this is evidence.

---

The Explant Decision: Prophylactic vs. Medically Indicated Removal

The FDA’s current position on asymptomatic patients

The FDA’s guidance is nuanced and worth reading precisely. For women with BIOCELL implants and no symptoms, the FDA does not recommend removal because the risk of BIA-ALCL, while elevated compared to other textured implants, remains low in absolute terms. The agency frames the calculus as: the risks of surgery (anesthesia complications, infection, hematoma, scarring) in an asymptomatic patient may outweigh the benefit of preventing a disease that has not yet manifested.

However, the FDA recommends that asymptomatic patients:

• Be aware of the recall and the BIA-ALCL risk
• Have access to the product recall information
• Work with their physician to monitor for new symptoms
• Make the removal decision jointly with their physician based on their individual risk tolerance

When removal becomes medically indicated

Removal becomes medically recommended when:

• A new late seroma develops around the implant (this warrants aspiration and cytology before explant, to guide surgical planning)
• BIA-ALCL is confirmed by pathology
• Capsular contracture causes significant pain or deformity
• Other complications arise attributable to the recalled device

The legal distinction matters

If you pursue a lawsuit, whether your removal was medically indicated (driven by diagnosis or significant complications) versus prophylactic (elected removal of an asymptomatic recalled device) affects your damages calculation. Medically indicated removal following a BIA-ALCL diagnosis yields documented damages — pathology costs, surgical fees, oncology visits, treatment — that are straightforwardly attributable to Allergan’s product. Prophylactic removal is more complex to value; some courts have recognized medical monitoring costs and the anxiety of living with a recalled device as compensable, others have not.

This is not to say prophylactic removal cases are worthless — it means the legal theory differs and requires a more nuanced argument. Your attorney will assess which framework applies to your specific facts.

---

How Bellwether Trials Work in Mass Tort MDLs

The purpose of test cases

In any MDL with hundreds or thousands of cases, it is impossible to try every case individually before exploring global settlement. Bellwether trials solve this by selecting a small number of representative cases — chosen by the parties jointly or by the court — and trying them first to verdict.

The jury’s reactions, the damages awarded, and the legal rulings that emerge from bellwether trials create shared knowledge for everyone in the MDL:

• Plaintiffs’ counsel learns which arguments resonate and which fall flat
• Defense counsel sees where their liability exposure is real
• Both sides get a data point for valuing the remaining cases

A high plaintiff verdict sends the message that juries believe Allergan’s conduct was unreasonable and that damages should be substantial — incentivizing Allergan to settle the broader docket rather than risk thousands of similar verdicts. A defense verdict or low damages award gives Allergan leverage in settlement talks.

The October 2026 trial and what to watch

The first bellwether trial in MDL 2921 is currently scheduled for October 19, 2026, involving a single plaintiff selected from a pool of six cases being developed. The issues the jury will be asked to decide include:

• Whether BIOCELL’s design was defective
• Whether Allergan’s warnings were inadequate
• Whether any failure to warn caused the plaintiff’s BIA-ALCL
• The appropriate measure of damages

The judge selects the specific trial case by June 30, 2026. Parties are engaged in discovery — exchanging internal Allergan documents about what the company knew and when — in parallel with trial preparation.

---

Understanding Federal Preemption in Medical Device Cases

This is one of the most technical but important legal concepts in this litigation, because it determines whether the case exists at all.

Why medical device makers often win preemption arguments

The Medical Device Amendments of 1976 (MDA) include an express preemption clause that bars states from imposing requirements “different from, or in addition to” federal device requirements. For devices that received FDA Premarket Approval (PMA) — the most rigorous FDA pathway, which BIOCELL products underwent — this has often meant that state tort claims are preempted.

The logic: if the FDA already reviewed and approved the device, Congress did not want 50 different states second-guessing that judgment through tort law. In practice, this has shielded device manufacturers from many state claims.

Why Allergan’s preemption defense failed here

The exception to preemption is what the Supreme Court called “parallel claims” — lawsuits claiming the manufacturer violated the federal requirements themselves, not that it should have done more than what federal law required. In MDL 2921, plaintiffs argued that Allergan violated FDA regulations by:

• Failing to file mandatory adverse event reports on BIA-ALCL cases in a timely manner
• Failing to comply with FDA reporting requirements regarding post-approval safety surveillance

Judge Martinotti found these allegations sufficient to let the cases proceed. The court did not rule that Allergan was liable — it ruled that plaintiffs had alleged a cognizable legal theory that deserved to go to discovery. This distinction between “allowed to proceed” and “won” is important; the liability question is still being developed through discovery and will be tested at the bellwether trial.

---

The Tax Treatment of Settlements: A Practical Guide

IRC Section 104 and the physical injury exclusion

Under Section 104(a)(2) of the Internal Revenue Code, damages received “on account of personal physical injuries or physical sickness” are excluded from gross income — meaning they are not taxable. BIA-ALCL is a physical illness caused by the defendant’s device; compensation for medical expenses, physical pain, and physical impairment related to it should generally qualify.

What may be taxable

Several categories of damages are taxable even in personal injury cases:

• Punitive damages: always taxable regardless of the nature of the underlying claim
• Emotional distress damages not related to physical injury: taxable; emotional distress arising from the physical sickness itself may be excludable, but stand-alone emotional distress unconnected to physical harm is not
• Interest on a settlement: any pre-judgment or post-judgment interest component is taxable as ordinary income
• Lost profits from a business: business income replacement is generally taxable

Practical steps after settlement

1. Ask your attorney to allocate the settlement amount explicitly between categories (physical injury compensation, emotional distress, punitive, lost wages) in the settlement agreement — explicit allocation shapes IRS treatment
2. Consult a CPA with experience in personal injury settlements before filing taxes in the year of settlement
3. Do not assume the full settlement is tax-free without verification

---

Monitoring Guidance After Explant: What the Guidelines Say

Whether you had your BIOCELL implants removed as part of BIA-ALCL treatment or prophylactically, post-explant monitoring protocols differ:

After BIA-ALCL treatment (surgical + any adjuvant therapy)

ASPS endorses the NCCN treatment guidelines, which recommend:

• PET/CT imaging at 3-to-6-month intervals for the first two years post-treatment
• Annual surveillance thereafter
• Physical examination at every follow-up visit
• Reporting any new swelling, mass, or systemic symptoms (fever, night sweats, unexplained weight loss) immediately

After prophylactic explant (no BIA-ALCL diagnosis)

Current guidelines do not specify a formal surveillance imaging protocol after prophylactic explant because, by definition, there is no disease to monitor. That said, standard breast health monitoring continues:

• Annual clinical breast examination
• Mammography screening per standard age-based guidelines (discuss the impact of prior implant history with your radiologist)
• Reporting any new breast changes to your physician

---

Conversations to Have With Your Plastic Surgeon Right Now

If you have confirmed BIOCELL implants and haven’t yet had a substantive conversation with a board-certified plastic surgeon about your specific situation, here are the concrete questions to raise:

About your implants:

• “Can you pull up my operative record and confirm the exact manufacturer and surface type of my implants?”
• “My records show [Allergan/Inamed/McGhan] — are these within the recalled BIOCELL product lines?”

About monitoring:

• “Given the recall, what monitoring schedule do you recommend for me specifically?”
• “If I develop a late seroma, what is your protocol for aspiration and cytology?”
• “At what point would you recommend imaging beyond what I already receive?”

About the removal decision:

• “Weighing my individual health history, age, and risk factors — what is your clinical recommendation on prophylactic removal versus ongoing monitoring?”
• “If I choose to keep the implants, what are the signs that would change your recommendation?”

About documentation:

• “If BIA-ALCL is ever diagnosed, what implant materials and pathology samples would you preserve for legal purposes?”

A surgeon who cannot answer these questions specifically — or who dismisses your BIOCELL concern — is not the right surgeon for your ongoing care in this context.

---

The Role of Expert Witnesses in MDL 2921

Why Daubert challenges determine whether the case goes to trial

In federal court, expert testimony must satisfy the standards established under Daubert v. Merrell Dow Pharmaceuticals (1993) and codified in Federal Rule of Evidence 702. A judge acts as a “gatekeeper,” determining whether a proposed expert’s methodology is scientifically reliable and whether the testimony will actually help the jury decide the case.

In medical device MDLs, Daubert challenges — motions to exclude opposing expert witnesses — are often the most consequential pretrial battles. If Allergan successfully excludes plaintiffs’ causation experts (the scientists who would testify that BIOCELL surface design specifically causes BIA-ALCL), many claims could collapse. If plaintiffs successfully exclude Allergan’s defense experts, the company’s liability defenses weaken substantially.

In MDL 2921, Judge Martinotti already permitted expert testimony linking BIOCELL implants to BIA-ALCL in a 2025 ruling — a significant milestone for plaintiffs. This means the core scientific causation argument survived the gatekeeping phase and will be presented to the jury at the October 2026 bellwether trial.

Types of experts both sides rely on

Plaintiffs’ experts typically include:

• Oncologists and hematologists specializing in lymphoma (establishing BIA-ALCL as a real disease caused by specific implant types)
• Materials scientists or biomedical engineers (establishing that BIOCELL’s surface design sheds particles that trigger immune response)
• Epidemiologists (establishing statistical association between BIOCELL and BIA-ALCL incidence)
• Regulatory experts (establishing what Allergan knew, when it knew it, and what FDA regulations required them to report)

Allergan’s defense experts typically include:

• Biomedical engineers challenging the causation mechanism
• Oncologists arguing alternative causes or that BIA-ALCL risk is inherent to any texturing
• Regulatory experts arguing Allergan complied with all FDA reporting obligations
• Damages experts challenging the valuation of future medical monitoring costs

Each expert’s deposition, methodology, and prior publications become potential ammunition for the other side. This is why the discovery phase has extended through late 2024 and into 2025.

---

Case Valuation: How Much Is a BIA-ALCL Lawsuit Worth?

There are no publicly confirmed individual settlement amounts in MDL 2921 that allow reliable case valuation as of this writing. Any attorney who quotes you a specific expected settlement amount before the first bellwether trial result is speculating, not calculating. However, the analytical framework attorneys use to value cases is transparent:

The components of a BIA-ALCL damages claim

Economic damages (objectively calculable):

• Past medical expenses: all costs of diagnosis, surgery, treatment, and follow-up care
• Future medical expenses: projected costs of surveillance imaging, oncology visits, potential treatment for recurrence (expert-testified present value calculation)
• Lost wages: income lost during treatment and recovery
• Diminished earning capacity: if BIA-ALCL treatment impaired your ability to return to prior employment

Non-economic damages (jury-valued):

• Physical pain and suffering during diagnosis, surgery, and treatment
• Emotional distress and anxiety — particularly the anxiety of living with a recalled device before diagnosis, and the uncertainty of recurrence risk after treatment
• Disfigurement: changes to appearance resulting from explant surgery, particularly in patients who decline reconstruction
• Loss of consortium: impact on the plaintiff’s spousal relationship (in jurisdictions that recognize this)

Punitive damages (where evidence supports it):

• Available in cases where plaintiffs demonstrate that Allergan acted with conscious disregard for patient safety — the delayed adverse event reporting argument is the primary vehicle here

Factors that strengthen case value

• Higher disease stage (more extensive treatment, clearer causation)
• Earlier implant placement (longer exposure to recalled device)
• Documented Allergan communications suggesting awareness of risk
• Clear, complete medical record documentation
• Consistent treatment timeline with no unexplained gaps

Factors that weaken case value

• Smooth implant mixed with BIOCELL (complicates causation)
• Pre-existing lymphoma or immune conditions
• Significant delay between symptom onset and seeking medical attention
• Incomplete documentation of expenses or lost wages

---

How MDL 2921 Compares to Other Major Medical Device Litigations

Understanding where MDL 2921 sits relative to comparable cases helps calibrate expectations:

MDL	Device	Peak Case Count	Resolution Status
MDL 2885 — 3M Combat Arms Earplugs	3M hearing loss	~230,000	Global settlement reached 2023 ($6B)
MDL 3014 — Philips CPAP/BiPAP	Philips sleep devices	~80,000+	Partial settlements ongoing
MDL 2570 — Cook Medical Filters	IVC filters	~16,000	Partial bellwether verdicts, ongoing settlement
MDL 2921 — Allergan BIOCELL	Breast implants	~1,456 (2025)	No global settlement; first trial Oct 2026

MDL 2921 is smaller in case count than the largest device MDLs because BIA-ALCL diagnosis is required for most claims — it’s not a medical monitoring class action. This actually cuts both ways: fewer plaintiffs means potentially higher per-case value if liability is established, but it also reduces Allergan’s pressure to offer a large global settlement just to clear the docket.

---

If Your Surgery Was Outside the United States

International patients and the MDL

MDL 2921 is a U.S. federal proceeding. If you received BIOCELL implants outside the United States and have not lived or been harmed within the U.S. jurisdictional framework, participation in MDL 2921 is generally not available.

However, Allergan’s worldwide recall means that this is not exclusively an American story. Women in Canada, Australia, the UK, and across Europe have pursued their own legal actions. In the UK, a woman in Sheffield received a five-figure settlement in November 2023 — the first publicly reported individual settlement in this litigation anywhere in the world, to the best of available reporting.

If you had surgery outside the US:

• Contact a product liability attorney in the country where you were implanted
• Research whether any class or group litigation has been organized in that jurisdiction
• Gather your records exactly as described in this article — the documentation approach is the same regardless of jurisdiction

If your surgery was in the US but you now live abroad

This situation is the clearest case for MDL 2921 participation. Many medical device law firms handle international clients remotely. The relevant jurisdiction is where the surgery was performed and where the harm occurred — not where you currently reside. A product liability attorney can take your initial consultation by video call.

---

What “Medical Monitoring” Claims Are — And Why They Matter

For women with confirmed BIOCELL implants who have not yet developed BIA-ALCL, the question of whether they have any legal claim is answered differently depending on whether the relevant state recognizes medical monitoring.

The theory of medical monitoring

A medical monitoring claim does not require a present injury. Instead, it asks: given that this plaintiff has been significantly exposed to a proven carcinogen or harmful product, should the defendant be required to pay for the ongoing surveillance needed to detect disease at the earliest possible stage?

The argument in the BIOCELL context: women with recalled implants face a documented 6-times-elevated risk of BIA-ALCL. They need regular ultrasound surveillance. That surveillance costs money. Allergan’s recalled product created the need for that monitoring. Allergan should fund it.

States that recognize medical monitoring

The availability of standalone medical monitoring claims (without present physical injury) varies significantly:

• States recognizing medical monitoring: California, New Jersey, Pennsylvania, and others have allowed it in various contexts
• States rejecting it without present injury: a significant number require a diagnosed physical injury
• MDL 2921 context: individual state law applies to each plaintiff’s claim; the MDL aggregates cases but does not create uniform substantive law

If you live in a medical monitoring-friendly state and have confirmed BIOCELL implants, an attorney can advise whether this avenue is viable for you specifically.

---

Practical Guide: Your First Call to a Product Liability Attorney

Most women who contact a law firm about BIA-ALCL/BIOCELL claims are unfamiliar with the legal process. Here is what typically happens on that first call, and how to prepare:

What the attorney will ask you

1. Implant identification: What manufacturer, product type, and do you have documentation?
2. Diagnosis: Have you been diagnosed with BIA-ALCL? If so, when, and what stage?
3. Treatment: What treatment have you undergone — surgery, chemotherapy, radiation?
4. Damages: Do you have medical bills? Were you unable to work? For how long?
5. Jurisdiction: Where was your surgery performed? Where do you currently live?
6. Timeline: When did you first notice symptoms? When did you first connect them to the implants?

What to bring or prepare before the call

• Your Device Identification Card or operative report (even a photo of it on your phone)
• A rough timeline of surgery date, symptom onset, diagnosis date, treatment dates
• A ballpark of medical bills incurred
• Any Allergan communications you’ve received about the recall

Questions to ask the attorney

• “Have you worked on MDL 2921 cases or similar medical device MDLs before?”
• “Is my case strong enough to be worth pursuing, in your honest assessment?”
• “What does your contingency fee agreement look like, and what litigation expenses would I be responsible for if we lose?”
• “How long do you realistically expect this process to take?”
• “What happens if I accept Allergan’s warranty reimbursement — does that affect my claim?”

A quality attorney will answer all of these directly. One who evades, makes promises of specific outcomes, or pressures you to sign quickly is a red flag.

---

Related Legal and Medical Resources

If you’re navigating the broader landscape of defective medical device and mass tort claims, these related articles may be useful:

• Hernia Mesh Lawsuit 2026
• Bard PowerPort Catheter Lawsuit 2026
• Exactech Knee and Hip Recall Lawsuit MDL 3044 2026
• Philips CPAP Recall Lawsuit MDL 3014 2026
• Medical Malpractice Lawsuit Guide 2026
• How Class Action Settlements Pay Out 2026
• Mass Tort Settlement Payout Timeline 2026
• Personal Injury Lawyer Fee Guide 2026
• Structured Settlement Cash-Out Guide 2026

---

Your Concrete Action Plan

If you’re not sure whether you have BIOCELL implants:

1. Search for your Device ID Card in your post-surgery paperwork
2. Call the hospital’s medical records department and request your operative report
3. Ask your current plastic surgeon to review your history

If you have confirmed BIOCELL implants but no symptoms:

1. Schedule an appointment with a board-certified plastic surgeon to establish a monitoring baseline
2. Ask specifically: “Given the BIOCELL recall, what monitoring protocol do you recommend for me?”
3. Know the warning signs (persistent late seroma, asymmetric swelling) and act immediately if they appear

If you have symptoms:

1. See a physician now — do not wait for your annual checkup
2. Request ultrasound evaluation of fluid around the implant
3. Insist on CD30 testing if fluid is found
4. If BIA-ALCL is confirmed, get an oncology referral and contact a product liability attorney within days

If you’ve already been diagnosed with BIA-ALCL:

1. Document every medical expense and appointment
2. Consult a product liability attorney specializing in MDL 2921 — initial consultations are free
3. Preserve all implant materials and pathology samples (your surgeon should do this — confirm it)
4. Do not accept any settlement or sign any release before speaking with an attorney

---

This article is provided for general information purposes only and does not constitute legal advice, medical advice, or a solicitation of legal representation. Medical decisions regarding breast implants should be made with a board-certified plastic surgeon. Legal decisions should be made in consultation with a licensed attorney who can evaluate your specific facts. Outcomes in litigation and medical treatment vary and cannot be guaranteed.